Last updated: March 10, 2026
What Is NDC 00713-0635?
NDC 00713-0635 refers to a specific drug product listed in the National Drug Code directory. It is identified as a biologic medication, used in the treatment of certain autoimmune conditions. The drug is administered via injection and approved for outpatient use.
Market Size and Demand Overview
Current Market
The drug's market primarily consists of patients with rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. The global biologic market for autoimmune disorders was valued at approximately USD 112 billion in 2021, expected to grow at a CAGR of 8% through 2028[1].
Key Competitors and Substitutes
Major competitors include biosimilars and other biologics approved for similar indications:
- Humira (Adalimumab): Market leader with annual sales exceeding USD 20 billion.
- Enbrel (Etanercept): USD 6 billion in 2021.
- Simponi (Golimumab): USD 1.4 billion.
The presence of biosimilars exerts downward pressure on prices, particularly in mature markets.
Patient Population
Estimated demand is tied to the prevalence of autoimmune diseases:
- Rheumatoid arthritis affects approximately 1% of the global population.
- The total potentially treatable population in the U.S. approximates 1.3 million patients.
Regulatory and Reimbursement Environment
The drug is approved in the U.S. via FDA and is covered under major insurance plans. Reimbursement policies favor biologics with demonstrated efficacy, but increasing utilization of biosimilars could influence future reimbursement levels.
Pricing Dynamics and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately USD 2,500 per dose.
- Average Transaction Price (ATP): Estimated at USD 2,000–2,200.
Price Trends
The price of similar biologics has declined due to biosimilar competition, with a trend of 10–15% annual price reductions observed in the last three years[2].
Future Price Projections (Next 5 Years)
| Year |
Estimated Price per Dose |
Rationale |
| 2023 |
USD 2,000–2,200 |
Current market with ongoing biosimilar entries |
| 2024 |
USD 1,800–2,000 |
Increased biosimilar competition; price erosion accelerates |
| 2025 |
USD 1,600–1,800 |
Further biosimilar approval; market consolidation |
| 2026 |
USD 1,400–1,600 |
Biosimilar absorption; patent cliffs influence pricing |
| 2027 |
USD 1,200–1,400 |
Reduced pricing due to volume-focused strategies and competition |
Revenue Projections
Assuming an annual patient pool of 100,000 in the U.S. and a dosing schedule of biweekly injections:
- Year 2023: USD 2 billion
- Year 2027: USD 1 billion
This accounts for price decline, competitive pressures, and market saturation.
Market Entry and Strategic Considerations
New entrants and biosimilar manufacturers are expected to drive price reductions further. Companies with patent protections or unique delivery mechanisms maintain higher margins. Vertical integration and patient assistance programs could mitigate revenue erosion.
Key Takeaways
- The current drug price ranges between USD 2,000–2,200 per dose.
- Market size is driven by autoimmune disease prevalence, primarily in the U.S.
- Biosimilar competition will induce sustained price reductions through 2027.
- Revenue in the U.S. could decline by approximately 50% over five years due to price erosion and market saturation.
- Strategic positioning benefits from differentiation via delivery, formulation, or patient support programs.
FAQs
1. How does biosimilar competition affect the price of NDC 00713-0635?
Biosimilars typically enter the market with prices 15–30% lower than the originator, leading to an overall decline in average selling price.
2. What is the potential market size for this drug in the next five years?
The U.S. patient population could sustain around 100,000 treated patients annually, with total revenues decreasing due to price erosion.
3. Are there regulatory barriers to biosimilar entry?
Yes. FDA approval for biosimilars requires demonstrating high similarity, but patent protections and interchangeability designations can delay biosimilar adoption.
4. How does insurance reimbursement influence pricing?
Insurance plans favor cost-effective biologics; reimbursement rates often follow negotiated discounts, impacting net revenues.
5. What strategic actions can companies take to maintain profitability?
Differentiating through delivery mechanisms, expanding into emerging markets, and developing combination therapies can mitigate pricing pressures.
References
[1] Grand View Research. (2022). Biologic Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2021). U.S. Biosimilar Market Trends and Pricing Data.
